S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Fed's Shocking New Plan to Control Your Money (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Fed's Shocking New Plan to Control Your Money (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Fed's Shocking New Plan to Control Your Money (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Fed's Shocking New Plan to Control Your Money (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
NASDAQ:STIM

Neuronetics - STIM Stock Forecast, Price & News

$2.92
+0.06 (+2.10%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.86
$3.01
50-Day Range
$2.81
$6.43
52-Week Range
$1.98
$6.95
Volume
87,275 shs
Average Volume
264,988 shs
Market Capitalization
$79.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.67

Neuronetics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
231.1% Upside
$9.67 Price Target
Short Interest
Healthy
1.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of Neuronetics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.97 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.32) to ($1.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

317th out of 999 stocks

Surgical & Medical Instruments Industry

29th out of 103 stocks


STIM stock logo

About Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Neuronetics Settles Litigation Against BrainsWay
See More Headlines
Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Company Calendar

Last Earnings
3/07/2023
Today
3/30/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STIM
Employees
175
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.67
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+231.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-37,160,000.00
Pretax Margin
-56.99%

Debt

Sales & Book Value

Annual Sales
$65.21 million
Book Value
$2.10 per share

Miscellaneous

Free Float
25,806,000
Market Cap
$79.48 million
Optionable
Not Optionable
Beta
2.03

Key Executives

  • Keith J. SullivanKeith J. Sullivan
    President, Chief Executive Officer & Director
  • Stephen FurlongStephen Furlong
    Chief Financial Officer, Treasurer & Executive VP
  • Cory Anderson
    SVP- Research & Development & Clinical Affairs
  • W. Andrew Macan
    Secretary, CCO, EVP & General Counsel
  • Sara Grubbs
    Chief Revenue Officer & Senior Vice President













STIM Stock - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STIM shares.
View STIM analyst ratings
or view top-rated stocks.

What is Neuronetics' stock price forecast for 2023?

2 equities research analysts have issued 1-year target prices for Neuronetics' shares. Their STIM share price forecasts range from $7.00 to $12.00. On average, they expect the company's share price to reach $9.67 in the next twelve months. This suggests a possible upside of 231.1% from the stock's current price.
View analysts price targets for STIM
or view top-rated stocks among Wall Street analysts.

How have STIM shares performed in 2023?

Neuronetics' stock was trading at $6.87 at the start of the year. Since then, STIM stock has decreased by 57.5% and is now trading at $2.92.
View the best growth stocks for 2023 here
.

Are investors shorting Neuronetics?

Neuronetics saw a increase in short interest in March. As of March 15th, there was short interest totaling 256,700 shares, an increase of 23.6% from the February 28th total of 207,700 shares. Based on an average trading volume of 266,600 shares, the short-interest ratio is presently 1.0 days. Approximately 1.0% of the shares of the company are short sold.
View Neuronetics' Short Interest
.

When is Neuronetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our STIM earnings forecast
.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) issued its earnings results on Tuesday, March, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.13. The business had revenue of $18.20 million for the quarter, compared to analyst estimates of $16.58 million. Neuronetics had a negative trailing twelve-month return on equity of 56.07% and a negative net margin of 56.99%.

What ETFs hold Neuronetics' stock?

ETFs with the largest weight of Neuronetics (NASDAQ:STIM) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics updated its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $15.00 million-$16.00 million, compared to the consensus revenue estimate of $16.71 million.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

(STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cannell Capital LLC (11.93%), Schroder Investment Management Group (3.22%), Silvercrest Asset Management Group LLC (2.90%), Divisadero Street Capital Management LP (2.33%), Morgan Stanley (1.61%) and First Eagle Investment Management LLC (1.35%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan.
View institutional ownership trends
.

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $2.92.

How much money does Neuronetics make?

Neuronetics (NASDAQ:STIM) has a market capitalization of $79.48 million and generates $65.21 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Neuronetics have?

The company employs 175 workers across the globe.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206.

This page (NASDAQ:STIM) was last updated on 3/30/2023 by MarketBeat.com Staff